Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis.
Carpenter EL, Van Decar S, Adams AM, O'Shea AE, McCarthy P, Chick RC, Clifton GT, Vreeland T, Valdera FA, Tiwari A, Hale D, Kemp Bohan P, Hickerson A, Smolinsky T, Thomas K, Cindass J, Hyngstrom J, Berger AC, Jakub J, Sussman JJ, Shaheen MF, Yu X, Wagner TE, Faries M, Peoples GE. Carpenter EL, et al. Among authors: peoples ge. J Immunother Cancer. 2023 Aug;11(8):e006665. doi: 10.1136/jitc-2023-006665. J Immunother Cancer. 2023. PMID: 37536936 Free PMC article. Clinical Trial.
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Amin A, Benavides LC, Holmes JP, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE. Amin A, et al. Among authors: peoples ge. Cancer Immunol Immunother. 2008 Dec;57(12):1817-25. doi: 10.1007/s00262-008-0509-2. Epub 2008 Apr 8. Cancer Immunol Immunother. 2008. PMID: 18392824 Free PMC article. Clinical Trial.
The E75 HER2/neu peptide vaccine.
Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. Mittendorf EA, et al. Among authors: peoples ge. Cancer Immunol Immunother. 2008 Oct;57(10):1511-21. doi: 10.1007/s00262-008-0540-3. Epub 2008 Jun 7. Cancer Immunol Immunother. 2008. PMID: 18536917 Free PMC article. Review.
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE. Holmes JP, et al. Among authors: peoples ge. Cancer. 2008 Oct 1;113(7):1666-75. doi: 10.1002/cncr.23772. Cancer. 2008. PMID: 18726994 Free article. Clinical Trial.
Overcoming cancer immune tolerance and escape.
Clifton GT, Peoples GE. Clifton GT, et al. Among authors: peoples ge. Clin Cancer Res. 2009 Feb 1;15(3):749-51. doi: 10.1158/1078-0432.CCR-08-2805. Clin Cancer Res. 2009. PMID: 19188142
240 results